Nothing Special   »   [go: up one dir, main page]

ATE475411T1 - Liposomenladung mit metallionen - Google Patents

Liposomenladung mit metallionen

Info

Publication number
ATE475411T1
ATE475411T1 AT02766998T AT02766998T ATE475411T1 AT E475411 T1 ATE475411 T1 AT E475411T1 AT 02766998 T AT02766998 T AT 02766998T AT 02766998 T AT02766998 T AT 02766998T AT E475411 T1 ATE475411 T1 AT E475411T1
Authority
AT
Austria
Prior art keywords
metal ions
liposome loading
liposome
loading
liposomes
Prior art date
Application number
AT02766998T
Other languages
English (en)
Inventor
Paul Tardi
Sharon Johnstone
Murray Webb
Marcel Bally
Sheela Abraham
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE475411T1 publication Critical patent/ATE475411T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
AT02766998T 2001-10-03 2002-10-03 Liposomenladung mit metallionen ATE475411T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US32667101P 2001-10-03 2001-10-03
US34152901P 2001-12-17 2001-12-17
US35675902P 2002-02-15 2002-02-15
US36207402P 2002-03-07 2002-03-07
US39427302P 2002-07-09 2002-07-09
PCT/CA2002/001501 WO2003028697A2 (en) 2001-10-03 2002-10-03 Liposome loading with metal ions

Publications (1)

Publication Number Publication Date
ATE475411T1 true ATE475411T1 (de) 2010-08-15

Family

ID=27541066

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02766998T ATE475411T1 (de) 2001-10-03 2002-10-03 Liposomenladung mit metallionen

Country Status (11)

Country Link
US (3) US7238367B2 (de)
EP (1) EP1432403B1 (de)
JP (2) JP4822666B2 (de)
AT (1) ATE475411T1 (de)
AU (1) AU2002331481B2 (de)
CA (1) CA2462376C (de)
DE (1) DE60237162D1 (de)
HK (1) HK1066731A1 (de)
IL (2) IL161187A0 (de)
TW (1) TWI235066B (de)
WO (1) WO2003028697A2 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100489701B1 (ko) * 2002-10-09 2005-05-16 주식회사 태평양 고농도의 트리터페노이드를 함유하는 미소화 리포좀 및 그제조방법
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
US7005140B2 (en) * 2003-03-31 2006-02-28 Alza Corporation Lipid particles having asymmetric lipid coating and method of preparing same
WO2004087104A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
US20040265368A1 (en) * 2003-04-02 2004-12-30 Lawrence Mayer Combination compositions of camptothecins and fluoropyrimidines
PT1744764E (pt) * 2004-04-22 2012-08-30 Celator Pharmaceuticals Inc Formulações lipossómicas de agentes antraciclina e análogos de citidina
AU2005240131C1 (en) 2004-05-03 2014-05-08 Ipsen Biopharm Ltd. Liposomes useful for drug delivery
US8658203B2 (en) * 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
WO2005117878A1 (ja) 2004-06-01 2005-12-15 Terumo Kabushiki Kaisha イリノテカン製剤
MX2007000359A (es) * 2004-07-09 2008-03-07 Robert Sabin Composiciones y metodos de uso para el tratamiento de enfermedades en mamiferos.
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
CA2582949A1 (en) * 2004-10-06 2006-04-13 Bc Cancer Agency Liposomes with improved drug retention for treatment of cancer
CA2584279C (en) * 2004-11-05 2015-01-27 Index Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal drug formulations
WO2006055903A1 (en) * 2004-11-18 2006-05-26 Celator Pharmaceuticals, Inc. Method for loading multiple agents into delivery vehicles
US20110020434A1 (en) * 2005-09-02 2011-01-27 O'halloran Thomas V Nanoparticle arsenic-platinum compositions
US8246983B2 (en) * 2005-09-02 2012-08-21 Northwestern University Encapsulated arsenic drugs
EP1976485A4 (de) * 2005-12-22 2011-10-26 Celator Pharmaceuticals Inc Liposomale formulierungen mit sekundären und tertiären aminen und herstellungsverfahren dafür
EP3219307B1 (de) * 2005-12-30 2021-09-08 NuVessl Inc. Nanolipidpartikel
SI2081551T1 (sl) * 2006-10-06 2013-05-31 Scil Technology Gmbh Tvorba posušenega rekonstituiranega vezikla za farmacevtsko uporabo
WO2008109032A2 (en) 2007-03-02 2008-09-12 Luna Innovations Incorporated Amphiphilic or lipophilic polar functionalized fullerenes and their uses
ES2550759T3 (es) 2007-08-17 2015-11-12 Celator Pharmaceuticals, Inc. Formulaciones farmacológicas de platino mejoradas
KR101085824B1 (ko) * 2009-03-11 2011-11-23 한국유나이티드제약 주식회사 생체적합성 고분자를 이용한 다기능성 조영제 및 이의 제조방법
US9814657B2 (en) 2009-04-27 2017-11-14 Premier Dental Products Company Buffered microencapsulated compositions and methods
US10688026B2 (en) 2009-04-27 2020-06-23 Premier Dental Products Company Buffered microencapsulated compositions and methods
DK177532B1 (en) * 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
JP2012236772A (ja) * 2009-09-28 2012-12-06 Terumo Corp スピカマイシン誘導体を有するリポソーム製剤
WO2011109334A2 (en) * 2010-03-01 2011-09-09 The Regents Of The University Of California Localization of agents at a target site with a composition and an energy source
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
PL226015B1 (pl) * 2011-03-03 2017-06-30 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna
KR101371698B1 (ko) * 2011-06-30 2014-03-07 한국화학연구원 진단 및 치료를 위한 이중기능성 리포솜 및 그의 제조방법
BR112014009305B1 (pt) 2011-10-21 2023-01-24 Celator Pharmaceuticals Inc. Composição lipossomal de fase gel liofilizada
JP6138140B2 (ja) * 2011-10-25 2017-05-31 ネクター セラピューティクス 癌患者の治療
US20150209281A1 (en) 2012-07-18 2015-07-30 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
ES2442450B1 (es) * 2012-08-09 2014-12-12 Enoc Solutions, S.L. Liposomas vacíos como adyuvante de diferentes principios activos, administrados independientemente y en su forma galénica convencional
KR102186116B1 (ko) 2012-11-20 2020-12-03 스펙트럼 파마슈티컬즈 인크 치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법
US9993427B2 (en) * 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
CN107073034B (zh) 2014-09-25 2020-11-03 第一牙科产品公司 可结合的微胶囊和表面官能化填料
WO2016069740A1 (en) * 2014-10-29 2016-05-06 The Regents Of The University Of California Bioactive delivery vehicles
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
BR112018006922B1 (pt) 2015-10-16 2023-11-21 Ipsen Biopharm Ltd Composições de irinotecano lipossômico estabilizado para armazenamento
BR112018013896A2 (pt) * 2016-01-07 2018-12-18 Western University Of Health Sciences formulações para o tratamento do câncer de bexiga
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
AU2021292747A1 (en) 2020-06-18 2023-02-23 Akagera Medicines, Inc. Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof
EP4188552A2 (de) 2020-07-28 2023-06-07 Jazz Pharmaceuticals Ireland Limited Kondensierte bicyclische raf-hemmer und verfahren zur verwendung davon
JP2023535595A (ja) 2020-07-28 2023-08-18 ジャズ ファーマシューティカルズ アイルランド リミテッド 縮合二環式ｒａｆ阻害剤のキラル合成
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
JP2023553343A (ja) 2020-11-25 2023-12-21 アカゲラ・メディスンズ，インコーポレイテッド 核酸を送達するための脂質ナノ粒子および関連する使用方法
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932657A (en) 1973-11-12 1976-01-13 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome encapsulation of chelating agents
JPS5933287A (ja) * 1982-08-19 1984-02-23 Hidetoshi Tsuchida 対面型ポルフイリン金属錯体を包接したリン脂質リポソ−ムおよび酸素吸脱着剤
JPS6176414A (ja) * 1984-09-21 1986-04-18 Shionogi & Co Ltd リポソーム製剤の製法
JPH0639382B2 (ja) * 1985-03-29 1994-05-25 財団法人生産開発科学研究所 リン脂質リポソ−ム
US4797285A (en) * 1985-12-06 1989-01-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Lipsome/anthraquinone drug composition and method
US4898735A (en) * 1985-12-06 1990-02-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Liposome/doxorubicin composition and method
JPH0751496B2 (ja) * 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5227170A (en) * 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
WO1990015595A1 (en) 1989-06-22 1990-12-27 Vestar, Inc. Encapsulation process
US5010073A (en) * 1989-10-05 1991-04-23 The Rockefeller University Use of liposomes as carriers for metalloporphyrins
US5270053A (en) * 1990-04-03 1993-12-14 Ciba-Geigy Corp. Parenterally administerable liposome formulation comprising synthetic lipid
DE4134158C2 (de) * 1991-10-11 1997-02-13 Max Delbrueck Centrum Verwendung von Carboplatin in lyotrophen Mesophasen zur Überwindung einer durch Zytostatika ausgelösten Leukopenie
WO1993026019A1 (en) 1992-06-08 1993-12-23 Molecular Bioquest, Inc. Preparation of controlled size inorganic particles for use in separations, as magnetic molecular switches, and as inorganic liposomes for medical applications
US6764693B1 (en) * 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
US6274116B1 (en) * 1993-06-03 2001-08-14 Reagents Of The University Of California Compositions for boron delivery to mammalian tissue
CA2126648C (en) * 1993-11-09 2000-10-10 Tomas De Paoli Liposomes containing bioavailable iron (ii) and method for obtaining them
DE4341479A1 (de) * 1993-12-02 1995-06-08 Deutsches Rheuma Forschungszen Verwendung von Metallothioneinen oder deren Apothioneinen zur Herstellung von Arzneimitteln mit antiviraler Wirkung
US5466467A (en) * 1994-03-30 1995-11-14 The United States Of America As Represented By The Secretary Of The Navy Liposomes containing polymerized lipids for non-covalent immobilization of proteins and enzymes
GB9420390D0 (en) 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
GB9500116D0 (en) * 1995-01-05 1995-03-01 Ciba Geigy Ag Pharmaceutical compositions
US5837282A (en) * 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US5843475A (en) * 1996-12-06 1998-12-01 Board Of Regents, The University Of Texas System Delivery and activation through liposome incorporation of diaminocyclohexane platinum (II) complexes
EP1087753A4 (de) * 1998-05-19 2004-06-30 Sdg Inc Zielgerichtetes liposomales arzneistoffverabreichungssystem
WO2001085131A2 (en) 2000-05-11 2001-11-15 Celator Technologies Inc. Lipid carrier compositions for improved drug retention
WO2001089653A2 (en) * 2000-05-23 2001-11-29 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Immobilized metalchelate complexes for catalysis and decontamination of pesticides and chemical warfare nerve-agents
US6416745B1 (en) * 2001-05-03 2002-07-09 Block Drug Company, Inc. Dental composition for treating hypersensitive teeth

Also Published As

Publication number Publication date
US20030091621A1 (en) 2003-05-15
IL161187A0 (en) 2004-08-31
JP2011157376A (ja) 2011-08-18
JP4822666B2 (ja) 2011-11-24
EP1432403A2 (de) 2004-06-30
US7744921B2 (en) 2010-06-29
WO2003028697A3 (en) 2003-05-30
IL161187A (en) 2012-10-31
DE60237162D1 (de) 2010-09-09
AU2002331481B2 (en) 2008-04-24
WO2003028697A2 (en) 2003-04-10
CA2462376A1 (en) 2003-04-10
JP2005508921A (ja) 2005-04-07
US7238367B2 (en) 2007-07-03
EP1432403B1 (de) 2010-07-28
US20060193904A1 (en) 2006-08-31
TWI235066B (en) 2005-07-01
US20080044464A1 (en) 2008-02-21
CA2462376C (en) 2010-12-14
HK1066731A1 (en) 2005-04-01

Similar Documents

Publication Publication Date Title
ATE475411T1 (de) Liposomenladung mit metallionen
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DE60201376D1 (de) Korrosionswiderstandsfähiger Seltenerdmetallmagnet und Herstellungsverfahren
HK1071640A1 (en) Housing made of fire-inhibiting material
BR0111541A (pt) Formulações lipossÈmicas inibidoras de timidilato sintase de benzoquinazolina
WO2003092632A3 (en) Cyclic peptide anti-cancer agents and methods
SE0300826L (sv) Leverans av emulsionssprängämnen
HUP0303649A3 (en) Liposome targeting of matrix metalloproteinase inhibitors
TR200402030T4 (tr) İkame edilen I-aminobutan-3-ol-türevleri
DE60025494D1 (de) Epothilon zusammensetzungen
AP2003002866A0 (en) Improved delivery of benefit agents.
DE50213942D1 (de) Eschichten von metallischen bauteilen
ITRM20010445A0 (it) Alfa-chetoglutarati di principi attivi e composizioni che li contengono.
AUPQ866500A0 (en) Therapeutic compounds and methods
AU2002352815A8 (en) Use of paecilomyces spp. as pathogenic agents against subterranean termites
DE60233455D1 (de) Becherförmiger Lautsprecheranker mit Neodymmagneten
ATE345778T1 (de) (ester)-lysolecithine in liposomen
DE50207379D1 (de) Nachweis von entzündungen
MY137953A (en) New association of an anti-atherothrombotic agent and an anti-platelet-aggregation agent
JP2004232179A5 (de)
FI20001483A0 (fi) Sijaintiriippuvaisten palvelujen toimittaminen
CA96910S (en) Flag
ITTO20000068V0 (it) Plantaroller massaggiatore, distensore e stimolatore dell'arco plantare.
CA96396S (en) Envelope
BG108165A (en) Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties